Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

Dupilumab significantly reduces severe exacerbations and improves lung function in children with moderate-to-severe type 2 ...

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's efficacy in children with atopic dermatitis and co ...

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

Earlier this year, researchers of Brigham and Women’s Hospital Harvard Medical School looked at clinical trials to show how six biologics, in particular, improve lung function; cut down on steroid use ...

Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...